Pila Pharma AB (FRA:5KC) Total Stockholders Equity: €1.35 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:5KC Pila Pharma AB FRA:5KC
47 GF Score
Price €0.16
GF Value €0.15
! 3 Warning Signs
View Full Analysis

What is Pila Pharma AB Total Stockholders Equity?

Pila Pharma AB FRA:5KC +16.54% 47 Total Stockholders Equity is €1.35 Mil as of Dec. 2025. GuruFocus rates FRA:5KC with a GF Score™ of 47/100 and a GF Value™ of €0.15. The stock has 3 warning signs investors should review.

Pila Pharma AB's Total Stockholders Equity for the quarter that ended in Dec. 2025 was €1.35 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Pila Pharma AB's Book Value per Share for the quarter that ended in Dec. 2025 was €0.03. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Pila Pharma AB's Debt-to-Equity for the quarter that ended in Dec. 2025 was 0.00.


Pila Pharma AB  (FRA:5KC) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Pila Pharma AB's Book Value per Share for the quarter that ended in Dec. 2025 is

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Pila Pharma AB's Debt-to-Equity for the quarter that ended in Dec. 2025 is

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pila Pharma AB Total Stockholders Equity Related Terms


Pila Pharma AB Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Pila Pharma AB's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pila Pharma AB Total Stockholders Equity Chart

Pila Pharma AB Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial 2.95 0.87 0.60 0.46 1.35

Pila Pharma AB Semi-Annual Data
Dec18 Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.60 0.23 0.46 0.11 1.35
FRA:5KC
47GF Score
Pila Pharma AB FRA:5KC
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of €1.35 Mil mean?
Pila Pharma AB (FRA:5KC) has a Total Stockholders Equity of €1.35 Mil as of Dec. 2025. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Pila Pharma AB and its competitors.
Is Pila Pharma AB's Total Stockholders Equity too high?
Pila Pharma AB's current Total Stockholders Equity is €1.35 Mil. Overall, Pila Pharma AB has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Pila Pharma AB's Total Stockholders Equity compare to VRTX and REGN?
Pila Pharma AB's Total Stockholders Equity of €1.35 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Pila Pharma AB and its competitors. Pila Pharma AB's current Total Stockholders Equity is €1.35 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pila Pharma AB stock overvalued right now?
Pila Pharma AB (FRA:5KC) has a current Total Stockholders Equity of €1.35 Mil. The stock's GF Value™ is €0.15, compared to a current price of €0.16 — trading 3.3% above its estimated fair value. The current Total Stockholders Equity is €1.35 Mil. Pila Pharma AB's overall GF Score™ is 47/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Pila Pharma AB (FRA:5KC), the current Total Stockholders Equity is €1.35 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pila Pharma AB (FRA:5KC) Overvalued in 2026?

Based on GuruFocus' analysis, Pila Pharma AB stock appears to be overvalued. The current stock price of €0.16 is trading 3.3% above its estimated GF Value™ of €0.15.

Key valuation signals for FRA:5KC:

  • Total Stockholders Equity: €1.35 Mil
  • GF Value™: €0.15 vs. price of €0.16 (3.3% above fair value)
  • GF Score™: 47/100 with 3 warning signs

No single metric tells the full story. See the FRA:5KC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pila Pharma AB Business Description

Other Exchanges PILA:Sweden
Address Norra Vallgatan 72, Malmo, SWE, 211 21
Pila Pharma AB is a clinical stage pharmaceutical company. It is developing a TRPV1 antagonist, XEN-D0501, as a novel type of oral anti-diabetic agent.
47GF Score

Get the complete analysis for FRA:5KC

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.16
Price
€0.15
GF Value